FDA clarifies policies for compounders as national GLP-1 supply …
Oct 3, 2024 · Tirzepatide injection has been in shortage since 2022 due to increased demand. FDA confirmed with the drug’s manufacturer that their stated product availability and manufacturing capacity can...
FDA Approves New Medication for Chronic Weight Management
The FDA approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition, for use in addition to a...
Compounding pharmacies can resume making tirzepatide as FDA ... - NBC News
6 days ago · Tirzepatide was on the FDA’s drug shortage list for nearly two years. ... It said at the time that pharmacies that produce large batches of medications would no longer be able to accept new ...
FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage
3 hours ago · After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA changed its mind and re-opened the door for GLP-1 compounders. Published Oct. 21, 2024. Amy Baxter Staff Reporter. An assortment of weight loss and diabetic drugs sit on a table in New South Wales, Australia, in May 2024.
FDA Says Compounding Pharmacies Can Keep Making Weight …
2 hours ago · On Friday, the FDA responded in a court filing that compounding pharmacies could continue making the drug while the agency re-evaluates its finding, NBC News reported. Shortages of tirzepatide ...
FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage …
5 days ago · The FDA has agreed to review its decision to remove Eli Lilly ’s LLY tirzepatide — the active ingredient used in diabetes drug Mounjaro and obesity drug Zepbound — from its shortage list ...
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight ...
Nov 8, 2023 · Zepbound™ (tirzepatide) injection is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥ 30 kg/m 2), or overweight (BMI ≥ 27 kg/m 2) with at least one weight-related comorbid condition. Zepbound is the first and only FDA-approved obesity treatment ...
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first …
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
F.D.A. Approves New Obesity Drug Tirzepatide That Will …
Nov 8, 2023 · The Food and Drug Administration on Wednesday approved an obesity drug from the company Eli Lilly that will be a direct competitor to the wildly popular Wegovy. The drug is called tirzepatide and...
News Release - Eli Lilly and Company
Aug 1, 2024 · Tirzepatide was approved by the FDA as Mounjaro ® for adults with type 2 diabetes to improve glycemic control on May 13, 2022, and as Zepbound ® for adults with obesity (a BMI of 30 kg/m 2 or greater) or those who are overweight (a BMI of 27 kg/m 2 or greater) who also have a weight-related comorbid condition on November 8, 2023. Both ...